Merck’s Keytruda has been found to reduce risk of death by 31% compared to chemotherapy, when used in previously treated patients with advanced esophageal or esophagogastric junction carcinoma, whose tumours express PD-L1.
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or those with locally advanced CSCC who are not candidates for surgery.